Cover Image
Market Research Report
Product code 
1066761

Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Opportunity Company Analysis

Published: | Renub Research | 170 Pages | Delivery time: 1-2 business days

Price

Back to Top
Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Opportunity Company Analysis
Published: March 1, 2022
Renub Research
Content info: 170 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Global Liquid Biopsy Market will reach US$ 8.1 Billion by 2027. Over the last decades, the vision of precision treatment has dramatically revitalized the field of medical oncology; the introduction of patient-tailored therapies has particularly enhanced all measurable outcomes. Liquid biopsy is a revolutionary technique that opens previously unexpected perspectives. Thus, Liquid biopsy is a non-invasive, convenient, fast, and reproducible sampling method that can reflect the changes in tumor gene manifestation profile and provide a strong base for individualized therapy and early cancer diagnosis. Furthermore, liquid biopsy clinical applications have focused on monitoring tumor progression, screening early cancer assessing therapeutic reaction & clinical prognosis, and detecting recurrent & refractory tumors. In addition, the liquid biopsy market is categorized into Kits & Consumables, Instruments, and Services.

Worldwide Liquid Biopsy Market Size was US$ 3 Billion in 2021

The liquid biopsy industry is experiencing growth due to an increased number of cancer patients, advancements such as next-generation sequencing for cancer patients in liquid biopsies, and improved patient preference for minimally invasive therapies. Besides, an upsurge in healthcare expenditure in developing countries, such as China and India, and liquid biopsy tests to treat rare cancers are anticipated to present ample opportunities for market growth. According to Renub Research Analysis, Global Liquid Biopsy Market will grow with 18% CAGR from 2021 - 2027.

COVID-19 Impact on Growth Trends of Liquid Biopsy Industry

The coronavirus disease has spread globally. Consequently, governments have assessed several rules and lockdowns worldwide, owing to an expansion in the number of coronavirus patients, affecting the market growth in the initial phase of the forecast period. This has resulted in the break of earlier diagnosis programs. Further, there has been a decrease in visits, therapies, screenings, and surgeries related to cancer, resulting in an increase in cancer morbidity in 2020. The pandemic has also affected the logistics and supplies of cancer diagnostic components, raw materials, and other essential commodities utilized in the production of liquid biopsy. These aspects restrict the growth of the liquid biopsy market during the COVID-19.

European Liquid Biopsy Market is rising due to the high Cases of Cancer

Geographically, liquid biopsy market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and LAMEA. The European liquid biopsy market is rising due to the high incidence of cancer and increasing medical costs. Consequently, the region is anticipated to multiply concerning the development and use of liquid biopsy techniques. Nowadays, in Europe, research and development on cancer diagnosis focus on liquid biopsy. Market participants and research institutes conduct extensive clinical trials to develop a sensitive liquid biopsy platform.

Lung Cancer Liquid Biopsy & Circulating Tumor DNA is anticipated to Dominate

On the basis of cancer type, the liquid biopsy market is classified into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, and Others. Lung cancer is anticipated to dominate the liquid biopsy market due to the increased prevalence of non-small cell lung cancer globally. For instance, as per the (WHO) World Health Organization, lung cancer is by far the highest cause of cancer death among female and male, estimated to have around 1.80 Million deaths worldwide in 2020.

Based on Circulating Biomarkers, the liquid biopsy industry includes Circulating Tumor cell (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), Other Biomarkers (cell-free DNA, etc.). In recent years, the circulating tumor cell segment has been increased due to the expanded number of clinically imperative tests with genomic analyses. Additionally, circulating tumor DNA is anticipated to be the fastest-growing segment during the forecast period, owing to the rapid development of (NGS) next-generation sequencing technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA).

Competitive Landscape

The global liquid biopsy market is highly fragmented into players like Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio - Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV.

Renub Research report titled "Liquid Biopsy Market Global Forecast by Regions (Europe, North America, Asia-Pacific Latin America, and Middle East/Africa),Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Companies (Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio - Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV)" Provides comprehensive details about Liquid Biopsy Industry.

Region - Market has been covered from 5 viewpoints

  • 1. North America
  • 2. Europe
  • 3. Asia - Pacific
  • 4. Latin America
  • 5. Middle East & Africa

Cancer - Market has been covered from 5 viewpoints

  • 1. Lung Cancer
  • 2. Breast Cancer
  • 3. Colorectal Cancer
  • 4. Prostate Cancer
  • 5. Others

Product - Market has been covered from 3 viewpoints

  • 1. Kits & Consumables
  • 2. Instruments
  • 3. Services

Circulating Biomarkers - Market has been covered from 4 viewpoints

  • 1. Circulating Tumor cell (CTCs)
  • 2. Circulating Tumor DNA (ctDNA)
  • 3. Extracellular Vesicles (EVs)
  • 4. Other Biomarkers (cell free DNA, etc)

Clinical Application - Market has been covered from 4 viewpoints

  • 1. Monitoring
  • 2. Prognosis
  • 3. Theranostics
  • 4. Screening

Sample - Market has been covered from 3 viewpoints

  • 1. Plasma / Serum
  • 2. Urine
  • 3. Others

All companies have been covered into 3 viewpoints

  • Overviews
  • Recent Developments
  • Revenues

Company Analysis

  • 1. Thermo Fisher Scientific, Inc
  • 2. Guardant Health, Inc
  • 3. EXACT Sciences Corp
  • 4. Illumina Inc.
  • 5. Bio - Rad Laboratories
  • 6. Biocept
  • 7. NeoGenomics, Inc.
  • 8. Qiagen NV.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global - Liquid Biopsy Market

6. Market Share - Global Liquid Biopsy

  • 6.1 By Region
  • 6.2 By Cancer
  • 6.3 By Product
  • 6.4 By Circulating Biomarkers
  • 6.5 By Sample

7. Region - Liquid Biopsy Market

  • 7.1 North America
  • 7.2 Europe
  • 7.3 Asia - Pacific
  • 7.4 Latin America
  • 7.5 Middle East & Africa

8. Cancer - Liquid Biopsy Market

  • 8.1 Lung Cancer
  • 8.2 Breast Cancer
  • 8.3 Colorectal Cancer
  • 8.4 Prostate Cancer
  • 8.5 Others

9. Product - Liquid Biopsy Market

  • 9.1 Kits & Consumables
  • 9.2 Instruments
  • 9.3 Services

10. Circulating Biomarkers - Liquid Biopsy Market

  • 10.1 Circulating Tumor cell (CTCs)
  • 10.2 Circulating Tumor DNA (ctDNA)
  • 10.3 Extracellular Vesicles (EVs)
  • 10.4 Other Biomarkers (cell free DNA, etc)

11. Clinical Application - Liquid Biopsy Market

  • 11.1 Monitoring
  • 11.2 Prognosis
  • 11.3 Theranostics
  • 11.4 Screening

12. Sample - Liquid Biopsy Market

  • 12.1 Plasma / Serum
  • 12.2 Urine
  • 12.3 Others

13. Porters Five Forces

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14. Company Analysis

  • 14.1 Thermo Fisher Scientific, Inc
    • 14.1.1 Overview
    • 14.1.2 Recent Development
    • 14.1.3 Financial Insights
  • 14.2 Guardant Health Inc
    • 14.2.1 Overview
    • 14.2.2 Recent Development
    • 14.2.3 Financial Insights
  • 14.3 EXACT Sciences Corp.
    • 14.3.1 Overview
    • 14.3.2 Recent Development
    • 14.3.3 Financial Insights
  • 14.4 Illumina Inc.
    • 14.4.1 Overview
    • 14.4.2 Recent Development
    • 14.4.3 Financial Insights
  • 14.5 Bio - Rad Laboratories
    • 14.5.1 Overview
    • 14.5.2 Recent Development
    • 14.5.3 Financial Insights
  • 14.6 Biocept
    • 14.6.1 Overview
    • 14.6.2 Recent Development
    • 14.6.3 Financial Insights
  • 14.7 NeoGenomics, Inc.
    • 14.7.1 Overview
    • 14.7.2 Recent Development
    • 14.7.3 Financial Insights
  • 14.8 Qiagen NV
    • 14.8.1 Overview
    • 14.8.2 Recent Development
    • 14.8.3 Financial Insights

List of Figures

  • Figure-01: Global - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-02: Global - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-03: North America - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-04: North America - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-05: Europe - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-06: Europe - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-07: Asia - Pacific - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-08: Asia - Pacific - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-09: Latin America - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-10: Latin America - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-11: Middle East & Africa - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-12: Middle East & Africa - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-13: Lung Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-14: Lung Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-15: Breast Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-16: Breast Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-17: Colorectal Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-18: Colorectal Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-19: Prostate Cancer - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-20: Prostate Cancer - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-21: Others - Liquid Biopsy Market (Million US$), 2016 - 2021
  • Figure-22: Others - Forecast for Liquid Biopsy Market (Million US$), 2022 - 2027
  • Figure-23: Product - Kits & Consumables Market (Million US$), 2016 - 2021
  • Figure-24: Product - Forecast for Kits & Consumables Market (Million US$), 2022 - 2027
  • Figure-25: Product - Instruments Market (Million US$), 2016 - 2021
  • Figure-26: Product - Forecast for Instruments Market (Million US$), 2022 - 2027
  • Figure-27: Product - Services Market (Million US$), 2016 - 2021
  • Figure-28: Product - Forecast for Services Market (Million US$), 2022 - 2027
  • Figure-29: Circulating Biomarkers - Circulating Tumor cell (CTCs) Market (Million US$), 2016 - 2021
  • Figure-30: Circulating Biomarkers - Forecast for Circulating Tumor cell (CTCs) Market (Million US$), 2022 - 2027
  • Figure-31: Circulating Biomarkers - Circulating Tumor DNA (ctDNA) Market (Million US$), 2016 - 2021
  • Figure-32: Circulating Biomarkers - Forecast for Circulating Tumor DNA (ctDNA) Market (Million US$), 2022 - 2027
  • Figure-33: Circulating Biomarkers - Extracellular Vesicles (EVs) Market (Million US$), 2016 - 2021
  • Figure-34: Circulating Biomarkers - Forecast for Extracellular Vesicles (EVs) Market (Million US$), 2022 - 2027
  • Figure-35: Circulating Biomarkers - Other Biomarkers (cell free DNA, etc) Market (Million US$), 2016 - 2021
  • Figure-36: Circulating Biomarkers - Forecast for Other Biomarkers (cell free DNA, etc) Market (Million US$), 2022 - 2027
  • Figure-37: Clinical Application - Monitoring Market (Million US$), 2016 - 2021
  • Figure-38: Clinical Application - Forecast for Monitoring Market (Million US$), 2022 - 2027
  • Figure-39: Clinical Application - Prognosis Market (Million US$), 2016 - 2021
  • Figure-40: Clinical Application - Forecast for Prognosis Market (Million US$), 2022 - 2027
  • Figure-41: Clinical Application - Theranostics Market (Million US$), 2016 - 2021
  • Figure-42: Clinical Application - Forecast for Theranostics Market (Million US$), 2022 - 2027
  • Figure-43: Clinical Application - Screening Market (Million US$), 2016 - 2021
  • Figure-44: Clinical Application - Forecast for Screening Market (Million US$), 2022 - 2027
  • Figure-45: Sample - Plasma / Serum Market (Million US$), 2016 - 2021
  • Figure-46: Sample - Forecast for Plasma / Serum Market (Million US$), 2022 - 2027
  • Figure-47: Sample - Urine Market (Million US$), 2016 - 2021
  • Figure-48: Sample - Forecast for Urine Market (Million US$), 2022 - 2027
  • Figure-49: Sample - Others Market (Million US$), 2016 - 2021
  • Figure-50: Sample - Forecast for Others Market (Million US$), 2022 - 2027
  • Figure-51: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2016 - 2021
  • Figure-52: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-53: Guardant Health , Inc - Global Revenue (Million US$), 2016 - 2021
  • Figure-54: Guardant Health , Inc - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-55: EXACT Sciences Corp. - Global Revenue (Million US$), 2016 - 2021
  • Figure-56: EXACT Sciences Corp. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-57: Illumina Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-58: Illumina Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-59: Bio - Rad Laboratories - Global Revenue (Million US$), 2016 - 2021
  • Figure-60: Bio - Rad Laboratories - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-61: Biocept - Global Revenue (Million US$), 2016 - 2021
  • Figure-62: Biocept - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-63: NeoGenomics, Inc. - Global Revenue (Million US$), 2016 - 2021
  • Figure-64: NeoGenomics, Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
  • Figure-65: Qiagen NV - Global Revenue (Million US$), 2016 - 2021
  • Figure-66: Qiagen NV - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

  • Table-01: Global - Liquid Biopsy Market Share by Region (Percent), 2016 - 2021
  • Table-02: Global - Forecast for Liquid Biopsy Market Share by Region (Percent), 2022 - 2027
  • Table-03: Global - Liquid Biopsy Market Share by Cancer (Percent), 2016 - 2021
  • Table-04: Global - Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 - 2027
  • Table-05: Global - Liquid Biopsy Market Share by Product (Percent), 2016 - 2021
  • Table-06: Global - Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 - 2027
  • Table-07: Global - Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2016 - 2021
  • Table-08: Global - Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 - 2027
  • Table-09: Global - Liquid Biopsy Market Share by Sample (Percent), 2016 - 2021
  • Table-10: Global - Forecast for Liquid Biopsy Market Share by Sample (Percent), 2022 - 2027